“ASSESSING THE LEADER TRIAL: UNDERSTANDING MYOCARDIAL INFARCTION SUBTYPES IN TYPE 2 DIABETES MELLITUS PATIENTS AND THE BENEFICIAL IMPACT OF LIRAGLUTIDE THERAPY”., SJHR-Africa, vol. 4, no. 12, p. 5, Dec. 2023, doi: 10.51168/sjhrafrica.v4i12.865.